SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 18)*

GT Biopharma, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

36254L308

(CUSIP Number)

05/29/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

36254L308

Names of Reporting Persons

Bristol Investment Fund, Ltd.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 74,524.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 74,524.00
8	Shared Dispositive Power 0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

74,524.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

2.367 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person: For Items 5 and 7: does not include shares underlying convertible preferred stock subject to a 9.9% beneficial ownership limitation

SCHEDULE 13G

CUSIP No.

36254L308

Names of Reporting Persons

Bristol Capital, LLC

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 150,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 150,000.00
8	Shared Dispositive Power 0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

4.76 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

GT Biopharma, Inc.

(b)

Address of issuer's principal executive offices:

505 Montgomery Street, 10th Floor, San Francisco, CA 94111

Item 2.

(a)

Name of person filing:

(i) Bristol Investment Fund, Ltd. (ii) Bristol Capital, LLC

(b)

Address or principal business office or, if none, residence:

(i) Citco Trustees (Cayman) Limited, 89 Nexus Way, Camana Bay, PO Box 311063, Grand Cayman KY1-1205, Cayman Islands (ii) 1090 Center Drive, Park City, UT 84098

(c)

Citizenship:

(i) Cayman Islands (ii) Delaware, USA

(d)

Title of class of securities:

Common Stock

(e)

CUSIP No.:

36254L308

Item 4.

Ownership

(a)

Amount beneficially owned:

(i) 74,524 (ii) 150,000

(b)

Percent of class:

(i) 2.367% (ii) 4.76% %

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

(i) 74,524 (ii) 150,000

(ii) Shared power to vote or to direct the vote:

(iii) Sole power to dispose or to direct the disposition of:

(i) 74,524 (ii) 150,000

(iv) Shared power to dispose or to direct the disposition of:

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Bristol Investment Fund, Ltd.

Signature:	/s/ Paul Kessler
Name/Title:	Paul Kessler, Director
Date:	06/02/2025

Bristol Capital, LLC

Signature:	/s/ Paul Kessler
Name/Title:	Paul Kessler, Manager, Bristol Capital, LLC
Date:	06/02/2025

Exhibit Information

Exhibit 1: Joint Filing Agreement